OSL

ONCOSIL FPO [OSL]
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Healthcare · ASX Small Cap
$1.2600 -3.1%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when OSL triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track OSL — Free

Active Signals

Bullish Signals

  • Above-average volume (1.7x) on a red day — sellers in control
  • Watch out — volume is flowing out even as price holds up. Distribution pattern
  • Took a hit — down 18.4% over the last 5 days
  • Beating the Small Ords index — relative strength of 2.13, so it's outpacing the pack
  • Trading above the 200-day average — the long-term trend is on your side
  • Critical cash runway (0.9 quarters)
  • Moderate P/S ratio (10.4x)
  • Strong revenue growth (+222%)
  • Small-cap ($20-100M)
  • CANSLIM S: Tight float (49%)
  • CANSLIM I: Institutional ownership (39%)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 62% over the past year
  • Revenue growing at +222% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (9.38%/day)
  • Beneish M-Score -1.60 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 11d (+5pts)

Risk Signals

  • Not enough chatter to gauge sentiment — defaulting to neutral
Ask Scout AI about OSL
"What's driving OSL today?" "How does OSL compare to peers?" "Key risks for OSL?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

HIGH OncoSil Medical Receives Saudi Arabia FDA Approval
NONE Application for quotation of securities - OSL
NONE OSPREY Registry Abstract Accepted for EANM 2026 Congress
NONE OncoSil Medical Completes Manufacturing Validation
LOW Investor Presentation
Announcement tone +3pts

Recent ASX Announcements

2026-07-19 OncoSil Medical Receives Saudi Arabia FDA Approval
2026-07-17 Application for quotation of securities - OSL
2026-07-14 Investor Presentation
2026-07-13 OSPREY Registry Abstract Accepted for EANM 2026 Congress
2026-07-12 OncoSil Medical Completes Manufacturing Validation PRICE SENSITIVE

Key Metrics

$38.9M
Market Cap
282K
Avg Volume
1.7x
Vol Ratio
$0.37 — $2.09
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-208.4%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 49%
LLeader vs LaggardpassRS: 71
IInstitutional SponsorshippassInst: 39%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:OSL vs IDTOSL vs ADROSL vs LDX
Scout Pro — Deeper Analysis for OSL
Try Pro free for 30 days
Share this analysis

Track OSL and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required